Mkt Cap$2.23T-1.74%
24h Vol$74.28B
BTC Dom56.3%
ETH Dom9.0%
F&G17Extreme Fear
BTC$62,686.00-1.67% ETH$1,666.62-3.16% USDT$0.9987-0.01% BNB$577.36-1.84% USDC$0.9996-0.01% XRP$1.10-1.88% SOL$69.40-3.23% TRX$0.329-1.01% FIGR_HELOC$1.03-0.16% HYPE$61.30-7.24% DOGE$0.0789-3.56% USDS$0.9997+0.00% RAIN$0.0157-2.06% LEO$9.49-0.84% ZEC$413.84-6.89% XLM$0.1911-3.05% BTC$62,686.00-1.67% ETH$1,666.62-3.16% USDT$0.9987-0.01% BNB$577.36-1.84% USDC$0.9996-0.01% XRP$1.10-1.88% SOL$69.40-3.23% TRX$0.329-1.01% FIGR_HELOC$1.03-0.16% HYPE$61.30-7.24% DOGE$0.0789-3.56% USDS$0.9997+0.00% RAIN$0.0157-2.06% LEO$9.49-0.84% ZEC$413.84-6.89% XLM$0.1911-3.05%
News

Weight Loss Drugs

Total Stories
3
Section
Weight Loss Drugs
Why Is Novo Nordisk (NVO) Stock Down 13% Premarket? Trial Fails to Match Eli Lilly
Market Analysis

Why Is Novo Nordisk Stock Down 13% Premarket? Trial Fails to Match Eli Lilly

Novo Nordisk stock plunged over 13% in premarket trading after its experimental obesity drug CagriSema failed to prove non-inferiority to Eli Lilly's tirzepatide in the REDEFINE 4 trial.

Tim FriesFeb 23, 20264 min read